STAC-9 explained

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.^{[1] [2] [3]}

See also

• SRT-1460
• SRT-1720
• SRT-2104
• SRT-2183
• SRT-3025

Notes and References

1. US . 9556201 . Ng PY, Blum C, Mcpherson L, Perni RB, Vu CB, Ahmed MM, Disch JS . Sitris Pharmaceuticals . GlaxoSmithKline . Bicyclic pyridines and analogs as sirtuin modulators. . 4 October 2012 .
2. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA . 6 . Evidence for a common mechanism of SIRT1 regulation by allosteric activators . Science . 339 . 6124 . 1216–9 . March 2013 . 23471411 . 10.1126/science.1231097 . 3799917 . 2013Sci...339.1216H .
3. Thevis M, Schänzer W . Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs . Rapid Communications in Mass Spectrometry . 30 . 5 . 635–51 . March 2016 . 26842585 . 10.1002/rcm.7470 . 2016RCMS...30..635T . 206444739 .